Publications by authors named "C B DAAMEN"
Dermatol Ther (Heidelb)
November 2023
Article Synopsis
- - Deucravacitinib is a newly approved oral medication for moderate to severe plaque psoriasis, showing better efficacy than apremilast and placebo in two phase 3 clinical trials.
- - A systematic review and network meta-analysis compared deucravacitinib with various systemic therapies, finding that it had the highest PASI 75 response rates among nonbiologic systemic treatments at different follow-up periods.
- - Patients taking deucravacitinib had higher chances of achieving significant improvement (PASI 75 response) compared to those treated with apremilast and methotrexate, particularly over mid- and long-term follow-ups.
